title: Prevalence and correlates of sleep disorders in Parkinson's disease: a polysomnographic study.
abstract: OBJECTIVE
  Sleep disorders in Parkinson's disease are very common. Polysomnography (PSG) is considered the gold standard for diagnosis. The aim of the present study is to assess the prevalence of nocturnal sleep disorders diagnosed by polysomnography and to determine the associated clinical factors.
  
  
  METHODS
  A total of 120 patients with Parkinson's disease were included. All patients underwent a standardized overnight, single night polysomnography.
  
  
  RESULTS
  Ninety-four (78.3%) patients had an abnormal PSG. Half of the patients fulfilled criteria for sleep apnea-hypopnea syndrome (SAHS); rapid eye movement behavior disorder (RBD) was present in 37.5%. Characteristics associated with SAHS were age (p = 0.049) and body mass index (p = 0.016). Regarding RBD, age (p < 0.001), left motor onset (p = 0.047) and levodopa equivalent dose (p = 0.002) were the main predictors.
  
  
  CONCLUSIONS
  SAHS and RBD were the most frequent sleep disorders. Higher levodopa equivalent dose and body mass index appear to be risk factors for RBD and SAHS, respectively.
authors: Unidad de Medicina del Sueño, Instituto Nacional de Neurología y Neurocirugía, Ciudad de México, México.
authors: Vanessa
authors: V
authors: Alatriste-Booth
authors: Clínica de Trastornos del Movimiento, Instituto Nacional de Neurología y Neurocirugía, Ciudad de México, México.
authors: Mayela
authors: M
authors: Rodríguez-Violante
authors: Clínica de Enfermedades Neurodegenerativas, Instituto Nacional de Neurología y Neurocirugía, Ciudad de México, México.
authors: Azyadeh
authors: A
authors: Camacho-Ordoñez
authors: Clínica de Enfermedades Neurodegenerativas, Instituto Nacional de Neurología y Neurocirugía, Ciudad de México, México.
authors: Amin
authors: A
authors: Cervantes-Arriaga
mesh_terms: D000368:Aged; D000978:Antiparkinson Agents / Q000009:adverse effects; D015992:Body Mass Index; D003430:Cross-Sectional Studies; D005260:Female; D006801:Humans; D007980:Levodopa / Q000009:adverse effects; D016015:Logistic Models; D008297:Male; D008800:Mexico / Q000453:epidemiology; D008875:Middle Aged; D010300:Parkinson Disease / Q000150:complications* / Q000188:drug therapy / Q000453:epidemiology / Q000503:physiopathology; D017286:Polysomnography; D015995:Prevalence; D020187:REM Sleep Behavior Disorder / Q000175:diagnosis* / Q000453:epidemiology / Q000209:etiology / Q000503:physiopathology; D012307:Risk Factors; D012737:Sex Factors; D012891:Sleep Apnea Syndromes / Q000175:diagnosis* / Q000453:epidemiology / Q000209:etiology / Q000503:physiopathology; D012895:Sleep, REM
chemical_list: D000978:Antiparkinson Agents; D007980:Levodopa